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Background: Attempts to improve survival outcomes of patients with high risk Ewing’s sar-
coma (ES) have focused on chemotherapy dose intensiﬁcation strategies.
Aim: The objective of this study is to retrospectively evaluate clinical characteristics and
outcome of pediatric patients with high risk ES treated at a single institution.
Materials and methods: From1995 to 2008, seventeen patients (male:female, 14:3) were treated
with dose-intensive therapy in our institution. Median age at diagnosis was 10 years (range:
2–15). Seven patients had metastases at diagnosis (lung in 6 cases and bone in one case).
Eleven patients presented with unresectable disease. Fifteen (88.2%) received the Spanish
Society of Pediatric Oncology protocol which includes six cycles of vincristine, doxorubicin,
ifosfamide and etoposide. Two out of the six cases that were resectable received postop-
erative radiation. In addition, eleven patients received deﬁnitive radiation therapy. Finally,
twelve (70.5%) out of 17 patients received myeloablative therapy with melphalan/etoposide.
The rest of patients (N=5) received busulfan/melphalan.
Results: Median follow-up was 78 months (range: 15–155 months). Initial responses were
complete in all patients, but 9 of themdevelopedprogressiondisease. Sevenpatients became
long-term event-free survivors. No patient died of toxicity after transplantation. The 2-
and 5-year overall survival rates for all patients were 93% and 73%, respectively. Event-freesurvival rates were 74% and 54% at 2 and 5 years, respectively.
Conclusion: This single-institution experience suggests that myeloablative therapy against
high risk ES is effective and safe.
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histologic appearance plus immunohistochemical, ultrastruc-
tural, or chromosomal ﬁndings consistent with the diagnosis
of ES. Staging studies included a technetium-99m bone scan,
computed tomography or magnetic resonance imaging, and164 reports of practical oncology an
1. Background
Ewing’s sarcoma (ES) is characterized by a chromosome 22
rearrangement, arises from bone or soft tissue, and pre-
dominantly affects children and young adults.1,2 The overall
incidence of ES seems to remain unchanged in the last
decades.3 Multimodality treatment programs achieve event-
free survival (EFS) rates of 60%. An axial skeleton location and
metastatic disease at diagnosis are well recognized adverse
factors.4,5 Up to one third of the patientswhosemetastases are
limited to the lungs and/or pleura become long-term survivors
with conventional chemotherapy, surgery, and radiother-
apy. Results are worse in patients with metastases to the
bone and/or bone marrow (BM). Recognition of this problem,
combined with improvements in supportive measures6 that
decrease toxicity risks,7 has led to a great interest in applying
chemotherapy dose intensiﬁcation strategies to improve the
prognosis of this subset of patients.
Autologous stem cell transplantation (ASCT) has been
employed as consolidation therapy for children with a variety
of high-risk solid tumors.8–11 The rationale for this approach
is that many of these tumors are sensitive to chemotherapy
and radiation, but because of steep dose–response curves to
both treatment modalities, relatively small dose reductions
can result in sharp decreases in log tumor cell kill. Phase I and
II studies have demonstrated the activity of high-dose mel-
phalan against tumors refractory to intensive conventional
chemotherapy.12,13 The dose-limiting toxicity of alkylating
agents, such as melphalan, busulfan and thiotepa is myelo-
suppression. This problem can be circumvented by rescue
with ASCT, thereby allowing a 3–10-fold dose escalation of
14those agents.
Table 1 – Patients with newly diagnosed ES treated with dose-i
Patient
No./sex
Age
(years)
Site of disease at
diagnosis
(primary/distant)
Local treatm
1/M 12 L-spine/lung Surgery
2/M 13 Pelvis/lung RT
3/F 10 Calcaneus Surgery
4/M 10 Pelvis/lung RT
5/F 13 Scapula/lung Surgery
6/M 13 Pelvis RT
7/M 7 Pelvis/lung RT
8/M 10 Rib Surgery, RT
9/M 7 Pelvis RT
10/M 3 L-spine RT
11/F 3 Pelvis RT
12/M 10 Femur Surgery, RT
13/M 2 L-spine/bone Surgery
14/M 11 L-spine RT
15/M 15 Pelvis/lung RT
16/M 8 Pelvis RT
17/M 8 L-spine RT
Abbreviations: M, male; F, female; B, bone metastasis; L, lung metastasis; B
CR, complete response; PD, progressive disease; RT, local radiotherapy.iotherapy 1 6 ( 2 0 1 1 ) 163–169
2. Aim
The objective of this study is to retrospectively evaluate our
single-institution experience of clinical characteristics and
outcomes of pediatric patients with high risk ES treated with
myeloablative therapy.
3. Materials and methods
3.1. Patients
We studied 17 patients with high-risk ES diagnosed from
1995 to 2008, most of whom (88.2%) were treated according
the Spanish Society of Pediatric Oncology (SEOP) protocol.15
All patients underwent myeloablative consolidation. Con-
siderations for high risk recurrence and indication for
dose-intensive/myeloablative therapy against Ewing’s sar-
coma were: (1) patients with non-metastatic axial skeleton
tumors; (2) patients with lung/pleural metastasis, if they dis-
appeared at week 18 after neoadjuvant chemotherapy; (3)
patients with multicentric tumor or with BM metastasis if
there was a response ≥50% at week 18 after neoadjuvant
chemotherapy.
The median age for all patients (male:female, 14:3) was 10
years (range: 2–15). The primary tumor involved the bone in all
patients (Table 1). Eleven (64.7%) presented with unresectable
disease at diagnosis. Pathologic criteria for ES were typicalntensive/myeloablative therapy.
ent Source of stem
cells
Follow-up, time from
diagnosis (transplant)
(months)
PB PD (L), 20 (15)
PB PD (LNA), 34 (20)
PB CR, 21 (17)
PB PD (L), 18 (7)
BM PD (B), 72 (62)
PB CR, 133+ (124+)
PB PD (B), 112 (104)
PB CR, 111+ (100+)
PB CR, 106+ (97+)
BM PD (B), 31 (21)
PB PD (B), 31 (21)
PB PD (L), 39 (24)
PB CR, 66+ (59+)
PB CR, 19+ (16+)
PB PD (L), 15 (8)
PB CR, 16+ (7+)
PB CR, 15+ (7+)
M, bone marrow; PB, peripheral-blood; LNA, location not available;
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istochemical evaluations of bilateral bone marrow aspira-
ions and biopsies. The TNM classiﬁcation according the
merican Joint Committee on Cancer 2002 staging system16
or bone cancer was as follows: 10 T1 and 7 T2; 17 N0; 10 M0,
M1a and 1 M1b.
.2. Treatment
nformed consents for all treatments were obtained in
ccordance with institutional review board guidelines. The
EOP15 protocol included six induction cycles of vincristine
1.5mg/m2, day 1), doxorubicin (20mg/m2, days 1–3. Alternat-
ng with actinomycin D 0.5mg/m2 before 2001), ifosfamide
2g/m2 before 2001 and 3g/m2 after 2001, days 1–3) and etopo-
ide (150mg/m2, days 1–3). Resectable tumors were removed
fter cycle 6. Consolidation chemotherapy was delivered after
urgery or after induction chemotherapy in unresectable
ases, and consisted of one cycle of vincristine 1.5mg/m2,
ctinomycin 0.75mg/m2 and cyclophosphamide 1500mg/m2.
fter consolidation chemotherapy, patients receivedmyeloab-
ative therapy followed by ASCT. Unresectable cases were
reated by radiation therapy for local control which was deliv-
red 8 weeks after the ASCT. The radiotherapy dose to the
rimary site was 48Gy in once-daily 1.8–2Gy for postoperative
adiation therapy and 55.2Gy in the setting of radiotherapy
s the sole modality for local control. The target volume
ncompassed the entire site as delineated at diagnosis, plus
-cm margins craniocaudal and 2-cm in the other directions.
etastatic sites were irradiated at the discretion of the treat-
ng physician.
Two cases were treated with a different protocol because
hey received the ASCT before the SEOP protocol was
mplemented at our institution. One of them was treated
ccording the T-9 protocol which consisted of ﬁve cycles of
ctinomycin D, doxorubicin, cyclophosphamide, vincristine,
ethotrexate, and bleomycin administered over a period of
5 weeks17 and the other one following the Memorial Sloan-
ettering Cancer Center P6 protocol,18 which includes cycles
f cyclophosphamide, doxorubicin, vincristine and cycles of
fosfamide/etoposide.
According to the SEOP protocol, the myeloablative regimen
ecommended is (stem-cell rescue was on day 0): busulfan
150mg/m2/day po, days −6 to −3)/melphalan (140mg/m2 by
0-min infusion on day −2). In our institution the regimen
elivered was (stem-cell rescue was on day 0): busulfan (days
7 to −4; 4mg/kg po every 6h if >6 years old or 10mg/kg po
id if ≤6 years old; the prescription for intravenous admin-
stration was: 1mg/kg every 6h if <9kg; 1.2mg/kg every 6h
f ≥9kg and <16kg; 1.1mg/kg every 6h if ≥16kg and <23kg;
.95mg/kg every 6h if ≥23kg and <34kg; 0.8mg/kg every 6h if
34kg)/melphalan (140mg/m2 by 30-min infusion on day −2).
regimen of melphalan (35mg/m2/day by 30-min infusion
n days −7 to −4)/etoposide (60mg/kg IV, day −3) was used
N=5) insteadof thepreviouslymentioned regimen inpatients
eceiving pulmonary radiation or if they had received radia-
ion therapy to the thorax or pelvis, due to potential increased
oxicity that could result from busulfan.
Patients given PBSCs (N=15) received the highest number
f nucleated cells (median: 5.5×108 kg−1, range: 0.49–10.2);
he median number of nucleated cells was 0.3×108 kg−1therapy 1 6 ( 2 0 1 1 ) 163–169 165
(range: 0.3–0.36) when the source of stem cells was the BM
(N=2). The highest median CD34+ cells/kg was contained in
the PB products (median: 4×106 kg−1, range: 1.8–12.6); the
CD34+ cells/kg in BM products ranged from 0.91×106 kg−1 to
1×106 kg−1.
3.3. Statistical analysis
Data regarding transplant patient characteristics, post trans-
plant follow up and outcomes were retrospectively collected
by our institutional data base. The Kaplan–Meier product limit
method was used to estimate survival. The criteria used to
determine objective tumor response for target lesions were
adapted from the original WHO Handbook and were recorded
as follows19: complete response (CR)—deﬁned as disappear-
ance of all target lesions; partial response—deﬁned as at least
a 30% decrease in the sum of the longest diameter of target
lesions, taking as reference thebaseline sum longest diameter;
progressive disease (PD)—at least a 20% increase in the sum of
the longest diameter of target lesions, taking as reference the
smallest sum longest diameter recorded since the treatment
started or the appearance of one or more new lesions; stable
disease (SD)—neither sufﬁcient shrinkage to qualify for partial
response nor sufﬁcient increase to qualify for progressive dis-
ease, taking as reference the smallest sum longest diameter
since the start of treatment.20
4. Results
4.1. Response
Initial responses to the SEOP protocol were CR in all patients;
the earliest PD was in patient number 15 (Table 1). Nine
patients developed distant recurrences after completing the
SEOP protocol. The sites of recurrence were the bone alone
(N=3), the lung alone (N=3), the bone and primary site (N=1),
and the lung and the primary site (N=1). The location of
distant progression of one patient was not reported. Eight
patients died from tumor progression 18 to 143 months after
diagnosis (Table 1).
Among the 12 patients (70.5%) treated with melpha-
lan/etoposide, seven died after recurrence (three relapsed 2–8
months after transplantation), while four patients remained
in CR after 5 years. In contrast, among patients treated with
busulfan/melphalan, therewere two relapses at 2–5 years after
transplantation.
4.2. Survival outcome
Nine of seventeen patients are alive and with no evidence
of disease, with seven being disease-free for more than 5
years (ﬁve of these patients received radiation therapy, four
as deﬁnitive local treatment and one postoperatively). Only
one of these patients had distant involvement at diagnosis
(bone metastasis). The median follow-up for all patients was
78 months (range: 15–155 months). The 2- and 5-year overall
survival (OS) rate for all patientswas 93% (95%CI: 81–105%) and
73% (95% CI: 51–95%), respectively (Fig. 1). EFS was 74% (95%
CI: 52–96%) and 54% (95% CI: 30–78%) at 2- and 5-year, respec-
166 reports of practical oncology and radiotherapy 1 6 ( 2 0 1 1 ) 163–169
Fig. 1 – Kaplan–Meier estimate of overall survival for all Fig. 3 – Kaplan–Meier curve for distant progression-freepatients.
tively (Fig. 2). The local control rate was 94% (95% CI: 84–104%)
at 2- and 5-year, respectively. Finally, we observed that 2- and
5-year distant progression-free survival rate (Fig. 3) was 74%
(95% CI: 52–96%) and 54% (95% CI: 30–78%), respectively.
5. Discussion
The Ewing’s family of tumors comprises 16% of primary
malignant bone tumors. This tumor is chemosensitive, and
multimodal therapy has signiﬁcantly improved outcome for
patients with ES.21 Despite these encouraging results, sub-
groups of patients who have a poor prognosis can be identiﬁed
(survival of 10–30% at 3 years). Poor prognostic features at ini-
tial presentation includemetastatic disease, particularly those
with bone or BM involvement, bulky disease (48 cm diameter)
Fig. 2 – Kaplan–Meier curve for event-free survival.survival for all patients.
at diagnosis, primary tumor involving axial or proximal loca-
tions (femur and humerus), shorter interval of EFS between
diagnosis and relapse22 and age older than 16 years.23 We
attempted to improve the prognosis in a cohort of patients
with high risk ES by using high-dose chemotherapy to achieve
remission followed by myeloablative therapy to consolidate
the disease response. Among our 17 patients, six patients
were prolonged (more than 5 years) relapse-free survivors.
The SEOP induction regimen and local treatment was success-
ful at achieving a complete response in all patients. However,
the myeloablative regimen failed to maintain remissions in
patients who had metastases to the lung at diagnosis. We
observed an EFS rate of 74% at 2 years. The recent addition of
ifosfamide and etoposide to conventional therapyhas resulted
in higher EFS rates in patients with local disease.21,24
EFS rates reported in the current study are difﬁcult to
compare to those reported by others25–27 due to the dif-
ferences in the deﬁnition of high-risk patients and the
differences in the megatherapy procedure. Successive stud-
ies at the National Cancer Institute used a regimen that
included relatively high doses of doxorubicin (75–90mg/m2)
and cyclophosphamide (1800mg/m2) ﬁrst as a short-term
induction preliminary to total body irradiation (TBI) based
consolidation28 and then intercalated with multiple cycles
of ifosfamide (9 g/m2)/etoposide (300 or 500mg/m2).29 This
change from a short-term induction with end-intensiﬁcation
to prolonged treatment with active combinations yielded
similar early response rates and no improvement in EFS.
Successive studies by cooperative groups in the United
States were marked ﬁrst by the addition of ifosfamide
(9 g/m2)/etoposide (500mg/m2) to standard-doses of vin-
cristine (1.5mg/m2), doxorubicin (75mg/m2), dactinomycin
(1.25mg/m2), and cyclophosphamide (1.2 g/m2),19 and then
by major increases in alkylator dosing with cycles that
included high-dose cyclophosphamide (2.2 or 4.2 g/m2) alter-
nating with cycles that included high-dose ifosfamide (14 or
12 g/m2).30,31 Prolonged30 or short-term31 use of these regi-
radio
m
(
P
i
a
p
o
c
i
E
i
s
u
d
d
C
e
d
G
S
m
g
s
a
E
d
d
p
t
s
c
m
f
2
r
m
w
m
r
c
a
s
m
m
p
n
u
t
a
E
o
w
o
m
m
t
e
t
oreports of practical oncology and
ens, or end-intensiﬁcation with TBI (12Gy) plus melphalan
180mg/m2)/etoposide (750mg/m2),31 did not improve EFS.
rolonged use of the protocol with augmented alkylator dos-
ng resulted in a 22.7% cumulative risk of secondary leukemia
t 4 years.32 In studies from the United Kingdom that used
rolonged treatments with modest dosing, improvement in
utcome was attributed to the replacement of low-dose
yclophosphamide (0.6 or 1.0 g/m2) by higher relative dos-
ng of ifosfamide (6 or 9 g/m2).33–35 In the large series of
S patients who received transplants in ﬁrst remission36,37
nduction protocols, myeloablative regimens, and sources of
tem cells varied greatly. Poor outcome was seen with the
se of the active agents for Escyclophosphamide, ifosfamide,
oxorubicin, dactinomycin, vincristine, and etoposideat stan-
ard dosages for prolonged periods of time (United Kingdom
hildren’s Cancer Study Group,34 European Intergroup Coop-
rative Ewing’s Sarcoma Study [EICESS]36) and at higher
osages in intensive regimens for short (Children’s Cancer
roup [CCG]31) or prolonged (Intergroup Ewing’s Sarcoma
tudies [IESS],30 St Jude38) periods of time. No improve-
ents in EFS rates occurred with successive cooperative
roup (US,30,31 German36) or large single-institution (St Jude38)
tudies that used increasingly aggressive chemotherapeutic
pproaches. Inclusion of ifosfamide with (IESS,30,31 St Jude,38
ICESS36,39) or without etoposide did not affect outcomes, nor
id consolidation of remission with myeloablative chemora-
iotherapy (CCG,31 EICESS36). The impact of megatherapy on
rognosis is obscured by the long-term survival with conven-
ional chemotherapy of some of these patients.
The importance of studying an unselected rather than a
elected group of patients when assessing treatment efﬁ-
acy has been emphasized elsewhere.8 Although reports on
yeloablative therapy do not give posttransplant EFS rates
or ES patients who had bone/BM metastases at diagnosis,
0–25% of these patients who receive transplants in ﬁrst
emission may become long-term survivors.36,40,41 Moreover,
arrow ablative conditioning regimens prior to stem cell
ith melphalan or busulfan-based combinations could be the
ost efﬁcient myeloablative scheme.42 Evidence of ES dose-
esponsiveness, the feasibility of dose-escalated conventional
hemotherapy, and the recognition of ifosfamide/etoposide
s an active combination in this disease has led to several
tudies aimed at exploiting these ﬁndings (without using
yeloablative consolidation). A variety of myeloablative regi-
ens without TBI have been tried against ES but none as the
lanned consolidation in a prospective study of newly diag-
osed patients. Melphalan has long been the most commonly
sed agent in myeloablative end-intensiﬁcation approaches
o ES. Exploratory studies on its use in high doses found
ctivity against refractory, large localized, and disseminated
S.43 Drabko et al.11 reported a probability of 2-year OS
f 0.68 and DFS of 0.63 in high-risk ES patients treated
ith melphalan-based megachemotherapy. Melphalan has
ften been combined with etoposide for synergistic antitu-
or effect. A de-emphasis on the use of that combination
ay be warranted in view of the preliminary analysis of
he 20-year European Bone Marrow Transplantation Registry
xperience which yielded results suggesting an advantage
o the use of busulfan. Oberlin et al. published the impact
f high-dose busulfan plus melphalan as consolidation intherapy 1 6 ( 2 0 1 1 ) 163–169 167
metastatic Ewing tumors in France.44 Seventy-ﬁve unselected
patients with newly diagnosed metastatic ES received high-
dose chemotherapy. The 5-year EFS rate for all 97 patients
was 37% and the OS rate was 38%. Patients obtained from
the Center for International Blood and Marrow Transplant
Research with localized and metastatic disease who received
ASCT as ﬁrst-line therapy had 5-year EFS of 51% and 60%,
respectively.45
The source of stem cells in most of the patients of our
study was PBSCs. Both autologous BM and PBSCs were sources
of stem cells in most myeloablative studies in the literature
involving ES; the use of PBSCs was stipulated in the CCG study
of unselected patients.31 An advantage of one autologous
stem-cell source over another was not evident. Nevertheless,
it is of interest to note that the degree of tumor contami-
nation seems to be lower in PBSC than in BM harvest.46,47
The consensus of two workshops on high-risk ES was that
allografting conferrednobeneﬁt, althoughavery limited expe-
rience with allogeneic BM rescue was deemed favorable in a
single-institution study (three of six patients relapse-free; no
further details).37 In vitro studies suggest that pharmacologic
purging may reduce the content of tumor cells in an autograft,
but cyclophosphamide derivatives have been withdrawn from
clinical use. Immunologic purging has not been described for
ES but a monoclonal antibody for that purpose has been iden-
tiﬁed and is being studied in a clinical trial.48
6. Conclusion
This single-institution experience in the context of ﬁndings
reported in the literature suggest that (a) distant and local
relapse remain the main obstacles to improving outcomes
in patients with high risk ES, (b) consolidation treatment
by megatherapy contributes to improved EFS rates in high-
risk patients compared with the historical experience, (c) a
major impact on prognosis awaits the introduction of entirely
novel therapies, and (d) major questions for the future to
be addressed prior to randomized studies include agreement
on the deﬁnition of high-risk patients and the most efﬁcient
megatherapy procedure. Continued investigation of ASCT as
a consolidation therapy in patients with high risk ES, a larger
number of study patients, and long-term clinical results are
needed.
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